DDInter894 DDInter1147
Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and adherence, the need for therapeutic monitoring, and serious side effects of secondary cancer and birth defects.
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Hydroxyurea {u} (Compound) resembles {v} (Compound) Acetohydroxamic acid
Hydroxyurea {u} (Compound) treats {v} (Disease) hematologic cancer
Hydroxyurea {u} (Compound) binds {v} (Gene) CYP2D6
Hydroxyurea {u} (Compound) is included by {v} (Pharmacologic Class) Urea
Hydroxyurea {u} (Compound) causes {v} (Side Effect) Infestation NOS
Hydroxyurea {u} may cause a minor interaction that can limit clinical effects when taken with {v} Trovafloxacin
Hydroxyurea {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Hydroxyurea {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentostatin
Hydroxyurea {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Hydroxyurea {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Hydroxyurea (Compound) resembles Acetohydroxamic acid (Compound)
Hydroxyurea (Compound) treats hematologic cancer (Disease)
Hydroxyurea (Compound) binds CYP2D6 (Gene)
Hydroxyurea (Compound) is included by Urea (Pharmacologic Class)
Hydroxyurea (Compound) causes Infestation NOS (Side Effect)
Hydroxyurea may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin
Hydroxyurea may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Hydroxyurea may lead to a major life threatening interaction when taken with Leflunomide